E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-motor symptoms in advanced Parkinson's disease |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced Parkinson's disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013113 |
E.1.2 | Term | Disease Parkinson's |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on non motor symptoms associated with advanced Parkinson's disease. |
|
E.2.2 | Secondary objectives of the trial |
To assess the effect of LCIG relative to that of OMT on the motor symptoms/motor complications, safety, tolerability and health-related outcome measures. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject must have a minimum PDSS-2 total score of 18 at Baseline assessment.
2. Subject must have a diagnosis of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria. See Appendix C for UKPDS.
3. Subject demonstrates persistent motor fluctuations in spite of individually optimized treatment.
4. The subject's Parkinson's disease is levodopa-responsive.
5. Subject has had optimal treatment with available anti-PD medication and their motor symptoms are judged inadequately controlled on this optimized treatment. Optimized treatment is defined as the maximum therapeutic effect obtained with pharmacological antiparkinsonian therapies when no further improvement is expected regardless of any additional manipulations of levodopa and/or other antiparkinsonian medication. This will be based on the Investigator's clinical judgment.
6. Subject and/or if applicable, their care-partner must be able to complete the Subject Dosing Diary and must be able to demonstrate the ability to operate, manipulate and care for the infusion pump and tubing.
|
|
E.4 | Principal exclusion criteria |
1. Subject's PD diagnosis is unclear or there is a suspicion that the subject has a parkinsonian syndrome such as secondary parkinsonism (e.g., caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome (e.g., Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body disease) or other neurodegenerative disease that might mimic the symptoms of PD.
2. Subject has undergone neurosurgery for the treatment of Parkinson's disease.
3. Subject has any neurological deficit that might interfere with the study assessments (e.g., hemiparesis).
4. Known hypersensitivity to levodopa, carbidopa or radiopaque material.
5. Subject has contraindications to levodopa, (e.g., narrow angle glaucoma, malignant melanoma).
6. Subject experiencing clinically significant sleep attacks or clinically significant impulsive behavior (e.g., pathological gambling, hypersexuality) at any point during the three months prior to the Screening evaluation) as judged by the Investigator.
7. Subject has discontinued apomorphine continuous infusion for the treatment of Parkinson's disease less than three months prior to screening visit. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Non-Motor Symptoms Scale (NMSS) Total Score and the Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, Week 6, Week 12, Week 26 |
|
E.5.2 | Secondary end point(s) |
Motor symptoms/motor complications will be measured by •Unified Parkinson's Disease Rating Scale (UPDRS) Parts III and IV
Safety and tolerability will be assessed by:
• Adverse event monitoring
• Neurological exams
• Clinical laboratory evaluations
• Electrocardiogram
• Vital signs and weight
• Columbia Suicide Severity Rating Scale (C-SSRS)
• Minnesota Impulsive Disorders Interview (MIDI)
● Sleep Attacks Questionnaire (SAQ)
Health Related Outcomes will be measured by:
• Parkinson's Disease Questionaire-8 (PDQ-8)
• Clinical Global Impression of Change (CGI-C)
• UPDRS Parts I and II
• Patient Global Impression of Change (PGIC)
• Montreal Cognitive Assessment Test (MOCA)
• PD Anxiety Index (PAS)
• Geriatric Depression Scale (GDS-15)
• King PD Pain Scale |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
UPDRS Parts III and IV:Screening, Baseline, Week6, Week 12, Week 26
Safety and Tolerability: every visit
HEOR: Baseline, Week 6, Week 12, Week 26 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
European Union |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 26 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 26 |